A committee established by the MDR-TB Working Group to review applications from potential MDR-TB pilot projects. The GLC determines whether projects meet criteria for receiving funding, helps to ensure programmatic success, and thereby to limit the possibility of creating drug resistance to second-line TB drugs - which are the last line of defense against TB.